Skip to main content
. 2021 Dec 28;11(1):86. doi: 10.3390/cells11010086

Figure 3.

Figure 3

TCS reduced HTR-8/SVneo and JEG-3 cells angiogenesis through PPARγ pathway. (A) TCS decreased the branch length of HTR-8/SVneo and JEG-3 cells. (B) Co-treated with TCS (40 µM for HTR-8/SVneo, 30 µM for JEG-3) in the absence or presence of rosiglitazone and GW9662 in these two cells. (C,D) PPARγ overexpression alleviated, while (C) PPARγ knockdown exacerbated. (D) TCS-induced cell angiogenesis inhibition of HTR-8/SVneo and JEG-3 cells. Scale bar: 400 µm. The data are shown as the means ± S.E.M. * p < 0.05; ** p < 0.01; compared with the indicated group, n = 3.